Related Experiment Video
Updated: May 10, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Predictors of publication of randomized controlled trials in nephrology
Background And Aims:
Changes in clinical practice based on research findings are dependent on the dissemination of information, which is a goal at national meetings. Given that evidence for many interventions in nephrology is lacking, it is important to determine predictors of publication of randomized controlled trials (RCTs) presented as abstracts at national conferences.
Materials And Methods:
All abstracts submitted to the American Society of Nephrology (ASN) meeting 2005 were reviewed to identify completed RCTs. Univariate logistic regression was used to compare characteristics between published RCTs until June 2010 and those not published. Time to publication was calculated.
Results:
73 completed RCTs were presented out of 4,280 abstracts. 53% of these were published; median time to publication was 24 months (13.36 IQR). Oral presentations were published more frequently (OR 3.66, p = 0.01) as well as those with stated industry funding (OR 2.92, p = 0.03) and larger sample sizes (OR 2.1, p = 0.01). Blinded RCTs had ~ 4 times the odds of being published. Only ten RCTs used clinical endpoints such as death, hospitalizations etc.; however, all reached publication.
Conclusions:
Almost 50% of RCTs presented at the ASN 2005 meeting were not published within the studied time-frame. Well-conducted RCTs enhance the body of evidence needed to care for patients, if published. It is important to identify characteristics associated with non-publication, as above, to help us perform and report our studies better.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted less...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...